BRIEF-Alvotech Signs U.S. Agreement To Expand Access For Newly Approved High-Concentration Interchangeable Biosimilar To Humira® (adalimumab)

Reuters04-19

April 19 (Reuters) - Alvotech SA :

* ALVOTECH SIGNS U.S. AGREEMENT TO EXPAND ACCESS FOR NEWLY APPROVED HIGH-CONCENTRATION INTERCHANGEABLE BIOSIMILAR TO HUMIRA® (ADALIMUMAB)

* ALVOTECH SA - CURRENT MULTI-PRODUCT COMMERCIALIZATION PARTNERSHIP BETWEEN TEVA PHARMACEUTICALS AND ALVOTECH REMAINS UNCHANGED

* ALVOTECH SA - AGREEMENT BROADENS PATIENT ACCESS AND FURTHER COMMITMENT TO AVAILABILITY OF VITAL BIOLOGICS IN U.S. AND GLOBALLY

* ALVOTECH SA - TEVA WILL CONTINUE TO COMMERCIALIZE ADALIMUMAB-RYVK UNDER SIMLANDI BRAND IN U.S

* ALVOTECH SA - LONG-TERM AGREEMENT WITH A STRATEGIC PARTNER TO FURTHER ENHANCE ACCESS TO ADALIMUMAB-RYVK IN U.S. MARKET

Source text for Eikon: Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428560976?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-19 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428560976","market":"us","top_or_hot":-1,"title":"BRIEF-Alvotech Signs U.S. Agreement To Expand Access For Newly Approved High-Concentration Interchangeable Biosimilar To Humira® (adalimumab)","media":"Reuters","content":"<html><body><p>April 19 (Reuters) - <a href=\"https://laohu8.com/S/ALVO\">Alvotech</a> SA   :</p><p>   * ALVOTECH SIGNS U.S. AGREEMENT TO EXPAND ACCESS FOR NEWLY APPROVED HIGH-CONCENTRATION INTERCHANGEABLE BIOSIMILAR TO HUMIRA® (ADALIMUMAB)</p><p>   * ALVOTECH SA - CURRENT MULTI-PRODUCT COMMERCIALIZATION PARTNERSHIP BETWEEN TEVA PHARMACEUTICALS AND ALVOTECH REMAINS UNCHANGED</p><p>   * ALVOTECH SA - AGREEMENT BROADENS PATIENT ACCESS AND FURTHER COMMITMENT TO AVAILABILITY OF VITAL BIOLOGICS IN U.S. AND GLOBALLY</p><p>   * ALVOTECH SA - TEVA WILL CONTINUE TO COMMERCIALIZE ADALIMUMAB-RYVK UNDER SIMLANDI BRAND IN U.S</p><p>   * ALVOTECH SA - LONG-TERM AGREEMENT WITH A STRATEGIC PARTNER TO FURTHER ENHANCE ACCESS TO ADALIMUMAB-RYVK IN U.S. MARKET</p><p>Source text for Eikon:    Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Alvotech Signs U.S. Agreement To Expand Access For Newly Approved High-Concentration Interchangeable Biosimilar To Humira® (adalimumab)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Alvotech Signs U.S. Agreement To Expand Access For Newly Approved High-Concentration Interchangeable Biosimilar To Humira® (adalimumab)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-19 20:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 19 (Reuters) - Alvotech SA   :   * ALVOTECH SIGNS U.S. AGREEMENT TO EXPAND ACCESS FOR NEWLY APPROVED HIGH-CONCENTRATION INTERCHANGEABLE BIOSIMILAR TO HUMIRA® (ADALIMUMAB)   * ALVOTECH SA - ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2428560976","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428560976","pubTimestamp":1713530963,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 19  - Alvotech SA   :   * ALVOTECH SIGNS U.S. AGREEMENT TO EXPAND ACCESS FOR NEWLY APPROVED HIGH-CONCENTRATION INTERCHANGEABLE BIOSIMILAR TO HUMIRA    * ALVOTECH SA - CURRENT MULTI-PRODUCT COMMERCIALIZATION PARTNERSHIP BETWEEN TEVA PHARMACEUTICALS AND ALVOTECH REMAINS UNCHANGED   * ALVOTECH SA - AGREEMENT BROADENS PATIENT ACCESS AND FURTHER COMMITMENT TO AVAILABILITY OF VITAL BIOLOGICS IN U.S. AND GLOBALLY   * ALVOTECH SA - TEVA WILL CONTINUE TO COMMERCIALIZE ADALIMUMAB-RYVK UNDER SIMLANDI BRAND IN U.S   * ALVOTECH SA - LONG-TERM AGREEMENT WITH A STRATEGIC PARTNER TO FURTHER ENHANCE ACCESS TO ADALIMUMAB-RYVK IN U.S. MARKETSource text for Eikon:    Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","BK4584":"避孕概念","BK4585":"ETF&股票定投概念","BK4559":"巴菲特持仓","BK4139":"生物科技","BK4588":"碎股","TEVA":"梯瓦制药","BK4007":"制药","BK4566":"资本集团","ALVO":"Alvotech"},"translate_title":"简介——Alvotech与美国签署协议，扩大新批准的高浓度可互换®生物仿制药（阿达木单抗）的准入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALVO":1,"TEVA":0.87},"content_text":"April 19 (Reuters) - Alvotech SA   :   * ALVOTECH SIGNS U.S. AGREEMENT TO EXPAND ACCESS FOR NEWLY APPROVED HIGH-CONCENTRATION INTERCHANGEABLE BIOSIMILAR TO HUMIRA® (ADALIMUMAB)   * ALVOTECH SA - CURRENT MULTI-PRODUCT COMMERCIALIZATION PARTNERSHIP BETWEEN TEVA PHARMACEUTICALS AND ALVOTECH REMAINS UNCHANGED   * ALVOTECH SA - AGREEMENT BROADENS PATIENT ACCESS AND FURTHER COMMITMENT TO AVAILABILITY OF VITAL BIOLOGICS IN U.S. AND GLOBALLY   * ALVOTECH SA - TEVA WILL CONTINUE TO COMMERCIALIZE ADALIMUMAB-RYVK UNDER SIMLANDI BRAND IN U.S   * ALVOTECH SA - LONG-TERM AGREEMENT WITH A STRATEGIC PARTNER TO FURTHER ENHANCE ACCESS TO ADALIMUMAB-RYVK IN U.S. MARKETSource text for Eikon:    Further company coverage:","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428560976"}